逸達生物科技 Foresee Pharmaceuticals Co., Ltd.
  • About Us
    • Company Profile
    • Business Model
    • Board of Directors
    • Management Team
    • Company Partners
    • Scientific Advisory Board
    • Others
  • R & D
    • Pipeline Overview
    • SIF Pipeline
      • FP-001:Prostate Cancer
      • FP-004:Opioid Dependence/Pain
      • FP-011:Breast Cancer/Prostate Cancer
      • FP-014:Breast Cancer/Prostate Cancer
      • FP-015:Neurology
      • Other Research Projects
    • NCE Pipeline
      • FP-045: Fanconi Anemia
      • FP-025:Asthma and COPD; ARDS in COVID-19 Patients
      • FP-040: CNS Diseases
      • FP-020: Alport Syndrome
  • Media
    • Press Release
    • Media Library
  • Investors
    • Corporate Governance
      • Corporate Structure
      • Board of Directors
      • Corporate Charters
      • Others
    • Material Information
    • News & Events
      • Press Releases
      • Events & Presentations
    • Financial Information
      • Financial Results
      • Monthly Revenues
    • Sharholder Information
      • Annual General Meeting
      • Major Shareholders
      • FAQs
      • Investor Contacts
    • Others
  • Career
    • WELFARE & BENEFITS
    • Join Us
  • Contact Us
  • 繁體中文
  • HOME
  • 繁體中文
  • HOME
Latest News
Foresee Pharmaceuticals Announces NDA for CAMCEVI™ 42MG Accepted for Review by the FDA
Foresee Pharmaceuticals to Present in 2020 Fanconi Anemia Scientific Symposium
Foresee Pharmaceuticals and Accord Healthcare Announce MAA Submission for CAMCEVI™ 42MG
  • Press Release

  • Pipeline Overview

  • Financial Information

  • Company Partners

Foresee Pharmaceuticals Co., Ltd.

Copyright © 2020 Foresee Pharmaceuticals Co., Ltd. All rights reserved.